Nimbus Therapeutics

We integrate computational chemistry and other advanced technologies to design breakthrough medicines and transform drug development.

[Nimbus Therapeutics @NimbusTx]

We are honored to welcome Dr. Katharine Knobil to our Board of Directors! She has more than 20 years of experience in #biopharma research and development with expertise in #oncology and #immunology. Learn more about this exciting phase of growth here: https://t.co/e1OfE4aktA

[Nimbus Therapeutics @NimbusTx]

On this #VeteransDay, we salute the brave individuals who have served our nation with honor and courage. Thank you for your sacrifice and dedication to safeguarding our freedom.

[Nimbus Therapeutics @NimbusTx]

Exciting news: @NewEnglandVC has nominated Nimbus for the 2023 NEVY Award for ‘Powerhouse Life Science Company of the Year'. Congratulations to our team, and we’re looking forward to celebrating all the #NEVYs23 nominees next month. https://t.co/IIGbjg4tpL

[Nimbus Therapeutics @NimbusTx]

Another impactful day at #SITC23 as Nimbus' David Ciccone presented preclinical data on our #HPK1 inhibitor, which support the potential for best-in-class selectivity among publicly disclosed HPK1 inhibitor programs to date. More on our Ph1/2 HPK1 program: https://t.co/6Vndhsve3o

[Nimbus Therapeutics @NimbusTx]

Today at #SITC23 we presented positive preliminary dose escalation data from our Ph 1/2 #HPK1 trial, showing monotherapy benefit in 3/13 evaluable patients, including complete response in 1 patient & prolonged stable disease in 2 patients. View our poster: https://t.co/yXs4tbRu5F

[Nimbus Therapeutics @NimbusTx]

Today we are sharing the first clinical data from our ongoing Phase 1/2 study of NDI-101150, our #HPK1 inhibitor in solid tumors, which will be presented at the @sitcancer Annual Meeting. Read more: https://t.co/RxfprWTShD #SITC23

[Nimbus Therapeutics @NimbusTx]

At the #FierceBiotechSummit, Nimbus CBO @AbbasRKazimi talked about the state of play for biotech M&A and how deals with larger companies can not only move novel medicines closer to patients, but also fuel discovery and development to bring the next breakthrough medicines forward.

[Nimbus Therapeutics @NimbusTx]

We are honored to be named as finalists for @Citeline's #ScripAwards2023 in the 'Licensing Deal of the Year' category. This recognition highlights our commitment to innovation through #drugdiscovery and impactful collaborations with pharma leaders like @TakedaPharma.

[Nimbus Therapeutics @NimbusTx]

Happening Today: Nimbus CBO @AbbasRKazimi discusses the future of #biopharma dealmaking alongside other industry experts at the 2023 @FierceBiotech Summit. More: https://t.co/vzev0ayCs5
#FierceBiotechSummit

[Nimbus Therapeutics @NimbusTx]

Tomorrow Nimbus’ David Ciccone will present preclinical data from our HPK1 inhibitor program — now in a Ph1/2 trial in #oncology — at #Targets23. Learn more: https://t.co/q1X8M8FaK7 @AACR @theNCI @EORTC

More on our HPK1 clinical trial: https://t.co/W40rabFNYg

[Nimbus Therapeutics @NimbusTx]

Today and every day, we stand with our LGBTQIA+ colleagues, friends and family in celebrating courage, love and authenticity. Happy #NationalComingOutDay.

[Nimbus Therapeutics @NimbusTx]

Today, we honor the resilience, culture and contributions of Indigenous communities in the United States.
#IndigenousPeoplesDay

[Nimbus Therapeutics @NimbusTx]

Nimbus CBO @AbbasRKazimi will join a panel of experts to discuss the evolving landscape of #biopharma dealmaking at the 2023 @FierceBiotech Summit. More about the #FierceBiotechSummit:  https://t.co/vzev0ayCs5

[Nimbus Therapeutics @NimbusTx]

Our Nimbi swung into action to benefit our community at the annual @LS_Cares Mini-Golf for Good event. Thank you to our friends at LSC Boston for organizing such a fun and impactful initiative each year.
#LSCImpact

[Nimbus Therapeutics @NimbusTx]

We are honored to receive @BiotechWkBoston's Deal of the Year Award recognizing the acquisition of our #TYK2 program and proud to share this moment with @TakedaPharma. This award recognizes our teams, deal-making and science, and honors collaboration to impact patients’ lives.

[Nimbus Therapeutics @NimbusTx]

This week Chief People Officer Erin Cowhig takes the stage at @BiotechWkBoston 's DE&I Summit to share how she has built inclusive talent pipelines throughout her career. The positive impacts of diverse talent on our work to develop #breakthroughmedicines are evident every day!

[Nimbus Therapeutics @NimbusTx]

Today Nimbus' Executive Director of Medicinal Chemistry, Silvana Leit, will present at the @RoySocChem 22nd Medicinal Chemistry Symposium on TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus and acquired by Takeda. More: https://t.co/9v3G9h4zLY

[Nimbus Therapeutics @NimbusTx]

We’re excited to announce a $210 million private financing to advance our next wave of tech-enabled small molecule medicines. Learn more: https://t.co/9fzwrp8KvA

[Nimbus Therapeutics @NimbusTx]

We are honored to be a finalist for @BiotechWkBoston’s Deal of the Year Award, recognizing the acquisition of our TYK2 inhibitor by Takeda, one of the largest single asset deals in all of biotech.

[Nimbus Therapeutics @NimbusTx]

This week, Nimbus' Director of Computational Chemistry, Leela Dodda, will present at the Gordon Research Conference on Medicinal Chemistry on how Nimbus uses physics-based machine learning to identify inhibitors for difficult to drug targets.